Report Information on Asia-Pacific Biomarkers for Hematopathology Market Research by Type (Products and Services), by Cancer Type (Lymphoma and Leukemia), by Technology Category (NGS, PCR, IHC, FISH and Others), by Region Forecast to 2032

It is anticipated that the Asia-Pacific Biomarkers for Hematopathology Market will experience a robust market expansion at a compound annual growth rate (CAGR) of 9.22% during the review period. Biomarkers for hematopathology are biological substances that are present in the blood, tissues, or bone marrow and serve as indicators for a variety of hematological disorders, including leukemia, lymphoma, anemia, and myeloproliferative disease. Modern diagnostic techniques, including flow cytometry, PCR, immunohistochemistry, and next-generation sequencing (NGS), are typically employed to detect and quantify these biomarkers, which are typically proteins, genes, or metabolites. Biomarkers are indispensable in the diagnosis, prognosis, and assessment of treatment efficacy of blood malignancies and other hematological disorders in the field of hematopathology.

The Asia-Pacific biomarkers for the hematopathology market are being driven by the increasing emphasis on early diagnosis and the increasing prevalence of blood-related malignancies. Additionally, the market is experiencing growth as a result of partnerships that are being formed to create biomarkers for blood malignancies. Furthermore, the Asia-Pacific biomarkers for hematopathology market is being constrained by a scarcity of trained professionals and a limited healthcare infrastructure in rural areas. Nevertheless, the market will experience development opportunities in the future due to the expanding geriatric population and the ongoing research to develop biomarkers for early detection.

Market Segmentation

The Asia-Pacific Biomarkers for Hematopathology market has been segmented into products and services based on type.

The lymphoma and leukemia cancer types have been used to segment the market. The Lymphoma segment was the most dominant segment in 2023 and is expected to continue to be the fastest-growing segment during the forecast period of 2024-2032.

The market has been segmented into NGS, PCR, IHC, FISH, and other categories based on technology.

A combination of factors, such as a rising incidence of hematological cancers, advancements in molecular diagnostics, and an increasing transition toward personalized and precision medicine, are driving the substantial growth of the Asia-Pacific (APAC) market for biomarkers in hematopathology. The region is experiencing an increase in the prevalence of hematological disorders, including leukemia, lymphoma, and myeloma. Consequently, the demand for advanced diagnostic tools and biomarkers that facilitate more precise and opportune detection has arisen. The incidence of leukemia, particularly acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), is increasing significantly. Biomarkers such as BCR-ABL1, FLT3, and IDH1/IDH2 are essential for the diagnosis, prognosis, and monitoring of treatment. For example, in 2020, 1,733,573 cancer cases were reported in South Asia, with leukemia comprising 62,163 (3.59%) of these cases. 36,315 men and 25,848 women were diagnosed with leukemia.

Major Players

F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Merck KGaA, Becton, Agilent Technologies Inc., Dickinson and Company, and PerkinElmer are the primary participants in the market.

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TECHNIQUE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 GROWING PREVALENCE OF BLOOD RELATED CANCERS
- 4.2.2 INCREASED FOCUS ON EARLY DIAGNOSIS
- 4.2.3 COLLABORATION TO DEVELOP BIOMARKER FOR BLOOD CANCER
4.3 RESTRAINTS
- 4.3.1 LIMITED HEALTHCARE INFRASTRUCTURE IN RURAL AREAS
- 4.3.2 SHORTAGES OF TRAINED PROFESSIONALS
4.4 OPPORTUNITY
- 4.4.1 GROWING GERIATRIC POPULATION
- 4.4.2 ONGOING RESEARCH TO DEVELOP BIOMARKER FOR EARLY DETECTION

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET
5.3 REIMBURSEMENT SCENARIO FOR IHC TESTING, BY COUNTRY
- 5.3.1 JAPAN
- 5.3.2 CHINA
- 5.3.3 SOUTH KOREA
- 5.3.4 INDIA
- 5.3.5 SINGAPORE
- 5.3.6 THAILAND
- 5.3.7 MALAYSIA
- 5.3.8 PHILIPPINES
5.4 REGULATORY FRAMEWORK FOR HEMATOPATHOLOGY BIOMARKER TESTING
- 5.4.1 AUSTRALIA
- 5.4.2 JAPAN
- 5.4.3 CHINA
- 5.4.4 SOUTH KOREA
- 5.4.5 INDIA
- 5.4.6 SINGAPORE
- 5.4.7 MALAYSIA
- 5.4.8 THAILAND
- 5.4.9 PHILIPPINES

6 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE

6.1 OVERVIEW
6.2 PRODUCT
6.3 SERVICE

7 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE

7.1 OVERVIEW
7.2 LYMPHOMA
7.3 LEUKEMIA

8 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY

8.1 OVERVIEW
8.2 NGS
8.3 PCR
8.4 IHC
8.5 FISH
8.6 OTHERS

9 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY COUNTRY

9.1 OVERVIEW
9.2 CHINA
9.3 JAPAN
9.4 INDIA
9.5 AUSTRALIA
9.6 SOUTH KOREA
9.7 TAIWAN
9.8 SINGAPORE
9.9 NEW ZEALAND
9.10 HONG KONG
9.11 THAILAND
9.12 INDONESIA
9.13 VIETNAM
9.14 MALAYSIA
9.15 PHILIPPINES

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 MARKET SHARE ANALYSIS, 2023 (IHC)
10.3 MARKET SHARE ANALYSIS, 2023
10.4 COMPETITOR DASHBOARD
10.5 PUBLIC PLAYERS STOCK SUMMARY
10.6 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
10.1 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.1.1 PRODUCT LAUNCH
- 10.1.2 PRODUCT APPROVAL

11 COMPANY PROFILES

11.1 F. HOFFMANN-LA ROCHE LTD.
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
11.2 MERCK KGAA
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 SWOT ANALYSIS
- 11.2.6 KEY STRATEGIES
11.3 AGILENT TECHNOLOGIES INC.
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 KEY STRATEGIES
11.4 PERKINELMER
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 KEY STRATEGIES
11.5 SAKURA FINETEK JAPAN CO., LTD.
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 KEY STRATEGIES
11.6 THERMO FISHER SCIENTIFIC INC.
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 SWOT ANALYSIS
- 11.6.6 KEY STRATEGIES
11.7 BECTON, DICKINSON AND COMPANY
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 SWOT ANALYSIS
- 11.7.6 KEY STRATEGIES
11.8 BIO-RAD LABORATORIES, INC.
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 SWOT ANALYSIS
- 11.8.6 KEY STRATEGIES
11.9 CELL SIGNALING TECHNOLOGY, INC.
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 KEY STRATEGIES
11.10 ABCAM LIMITED
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 PRODUCTS OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 KEY STRATEGIES

12 DATA CITATIONS

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019-2032 (USD THOUSANDS)
TABLE 3 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, FOR PRODUCT, BY COUNTRY, 2019-2032 (USD THOUSANDS)
TABLE 4 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, FOR SERVICE, BY COUNTRY, 2019-2032 (USD THOUSANDS)
TABLE 5 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (USD THOUSANDS)
TABLE 6 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (VOLUME)
TABLE 7 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, FOR LYMPHOMA, BY COUNTRY, 2019-2032 (USD THOUSANDS)
TABLE 8 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, FOR LEUKEMIA, BY COUNTRY, 2019-2032 (USD THOUSANDS)
TABLE 9 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019-2032 (USD THOUSANDS)
TABLE 10 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, FOR NGS, BY COUNTRY, 2019-2032 (USD THOUSANDS)
TABLE 11 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, FOR PCR, BY COUNTRY, 2019-2032 (USD THOUSANDS)
TABLE 12 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, FOR IHC, BY COUNTRY, 2019-2032 (USD THOUSANDS)
TABLE 13 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, FOR FISH, BY COUNTRY, 2019-2032 (USD THOUSANDS)
TABLE 14 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, FOR OTHERS, BY COUNTRY, 2019-2032 (USD THOUSANDS)
TABLE 15 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY COUNTRY, 2019-2032 (USD THOUSANDS)
TABLE 16 CHINA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019-2032 (USD THOUSANDS)
TABLE 17 CHINA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (USD THOUSANDS)
TABLE 18 CHINA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (VOLUME)
TABLE 19 CHINA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019-2032 (USD THOUSANDS)
TABLE 20 JAPAN BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019-2032 (USD THOUSANDS)
TABLE 21 JAPAN BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (USD THOUSANDS)
TABLE 22 JAPAN BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (VOLUME)
TABLE 23 JAPAN BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019-2032 (USD THOUSANDS)
TABLE 24 INDIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019-2032 (USD THOUSANDS)
TABLE 25 INDIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (USD THOUSANDS)
TABLE 26 INDIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (VOLUME)
TABLE 27 INDIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019-2032 (USD THOUSANDS)
TABLE 28 AUSTRALIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019-2032 (USD THOUSANDS)
TABLE 29 AUSTRALIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (USD THOUSANDS)
TABLE 30 AUSTRALIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (VOLUME)
TABLE 31 AUSTRALIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019-2032 (USD THOUSANDS)
TABLE 32 SOUTH KOREA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019-2032 (USD THOUSANDS)
TABLE 33 SOUTH KOREA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (USD THOUSANDS)
TABLE 34 SOUTH KOREA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (VOLUME)
TABLE 35 SOUTH KOREA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019-2032 (USD THOUSANDS)
TABLE 36 TAIWAN BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019-2032 (USD THOUSANDS)
TABLE 37 TAIWAN BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (USD THOUSANDS)
TABLE 38 TAIWAN BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (VOLUME)
TABLE 39 TAIWAN BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019-2032 (USD THOUSANDS)
TABLE 40 SINGAPORE BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019-2032 (USD THOUSANDS)
TABLE 41 SINGAPORE BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (USD THOUSANDS)
TABLE 42 SINGAPORE BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (VOLUME)
TABLE 43 SINGAPORE BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019-2032 (USD THOUSANDS)
TABLE 44 NEW ZEALAND BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019-2032 (USD THOUSANDS)
TABLE 45 NEW ZEALAND BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (USD THOUSANDS)
TABLE 46 NEW ZEALAND BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (VOLUME)
TABLE 47 NEW ZEALAND BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019-2032 (USD THOUSANDS)
TABLE 48 HONG KONG BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019-2032 (USD THOUSANDS)
TABLE 49 HONG KONG BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (USD THOUSANDS)
TABLE 50 HONG KONG BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (VOLUME)
TABLE 51 HONG KONG BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019-2032 (USD THOUSANDS)
TABLE 52 THAILAND BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019-2032 (USD THOUSANDS)
TABLE 53 THAILAND BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (USD THOUSANDS)
TABLE 54 THAILAND BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (VOLUME)
TABLE 55 THAILAND BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019-2032 (USD THOUSANDS)
TABLE 56 INDONESIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019-2032 (USD THOUSANDS)
TABLE 57 INDONESIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (USD THOUSANDS)
TABLE 58 INDONESIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (VOLUME)
TABLE 59 INDONESIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019-2032 (USD THOUSANDS)
TABLE 60 VIETNAM BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019-2032 (USD THOUSANDS)
TABLE 61 VIETNAM BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (USD THOUSANDS)
TABLE 62 VIETNAM BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (VOLUME)
TABLE 63 VIETNAM BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019-2032 (USD THOUSANDS)
TABLE 64 MALAYSIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019-2032 (USD THOUSANDS)
TABLE 65 MALAYSIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (USD THOUSANDS)
TABLE 66 MALAYSIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (VOLUME)
TABLE 67 MALAYSIA BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019-2032 (USD THOUSANDS)
TABLE 68 PHILIPPINES BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2019-2032 (USD THOUSANDS)
TABLE 69 PHILIPPINES BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (USD THOUSANDS)
TABLE 70 PHILIPPINES BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2019-2032 (VOLUME)
TABLE 71 PHILIPPINES BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2019-2032 (USD THOUSANDS)
TABLE 72 PRODUCT LAUNCH
TABLE 73 PRODUCT APPROVAL
TABLE 74 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
TABLE 75 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
TABLE 76 MERCK KGAA: PRODUCTS OFFERED
TABLE 77 AGILENT TECHNOLOGIES INC.: PRODUCTS OFFERED
TABLE 78 AGILENT TECHNOLOGIES INC.: PRODUCTS OFFERED
TABLE 79 PERKINELMER: PRODUCTS OFFERED
TABLE 80 SAKURA FINETEK JAPAN CO., LTD.: PRODUCTS OFFERED
TABLE 81 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 82 BECTON, DICKINSON AND COMPANY: PRODUCT OFFERED
TABLE 83 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
TABLE 84 CELL SIGNALING TECHNOLOGY, INC.: PRODUCTS OFFERED
TABLE 85 ABCAM LIMITED: PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET: STRUCTURE
FIGURE 2 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032)
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET
FIGURE 6 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, TYPE SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD THOUSANDS)
FIGURE 7 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TYPE, 2023 & 2032 (USD THOUSANDS)
FIGURE 8 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET SHARE (%), BY TYPE, 2023
FIGURE 9 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, CANCER TYPE SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD THOUSANDS)
FIGURE 10 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY CANCER TYPE, 2023 & 2032 (USD THOUSANDS)
FIGURE 11 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET SHARE (%), BY CANCER TYPE, 2023
FIGURE 12 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, TECHNOLOGY SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD THOUSANDS)
FIGURE 13 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY TECHNOLOGY, 2023 & 2032 (USD THOUSANDS)
FIGURE 14 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET SHARE (%), BY TECHNOLOGY, 2023
FIGURE 15 ASIA-PACIFIC MARKET ANALYSIS: BIOMARKERS FOR HEMATOPATHOLOGY MARKET, 2019-2032 (USD THOUSANDS)
FIGURE 16 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET, BY COUNTRY, 2023 & 2032 (USD THOUSANDS)
FIGURE 17 ASIA-PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET SHARE (%), BY COUNTRY, 2023
FIGURE 18 ASIA PACIFIC IHC BIOMARKERS FOR HEMATOPATHOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023
FIGURE 19 ASIA PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023
FIGURE 20 COMPETITOR DASHBOARD: ASIA PACIFIC BIOMARKERS FOR HEMATOPATHOLOGY MARKET
FIGURE 21 F. HOFFMANN-LA ROCHE LTD.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
FIGURE 23 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 MERCK KGAA: SWOT ANALYSIS
FIGURE 25 AGILENT TECHNOLOGIES INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 PERKINELMER: FINANCIAL OVERVIEW SNAPSHOT 106 THIS IS A PRIVATELY HELD COMPANY. THEREFORE, FINANCIALS ARE NOT AVAILABLE IN THE PUBLIC DOMAIN.
FIGURE 27 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
FIGURE 29 BECTON, DICKINSON AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 BECTON, DICKINSON AND COMPANY: SWOT ANALYSIS
FIGURE 31 BIO-RAD LABORATORIES, INC.: FINANCIAL OVERVIEW
FIGURE 32 BIO-RAD LABORATORIES, INC: SWOT ANALYSIS